The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
=== ColdFusion and Java === The standard ColdFusion installation allows the deployment of ColdFusion as a WAR file or EAR file for deployment to standalone application servers, such as Macromedia JRun, and IBM WebSphere. ColdFusion can also be deployed to servlet containers such as Apache Tomcat and Mortbay Jetty, but because these platforms do not officially support ColdFusion, they leave many of its features inaccessible. As of ColdFusion 10 Macromedia JRun was replaced by Apache Tomcat. Because ColdFusion is a Java EE application, ColdFusion code can be mixed with Java classes to create a variety of applications and use existing Java libraries. ColdFusion has access to all underlying Java classes, supports JSP custom tag libraries, and can access JSP functions after retrieving the JSP page context (GetPageContext()). Prior to ColdFusion 7.0.1, ColdFusion components could only be used by Java or .NET by declaring them as web services. However, beginning in ColdFusion MX 7.0.1, ColdFusion components can now be used directly within Java classes using the CFCProxy class. Recently, there has been much interest in Java development using alternate languages such as Jython, Groovy and JRuby. ColdFusion was one of the first scripting platforms to allow this style of Java development.
=== Drainage === Aqueous humor is continually produced by the ciliary processes and this rate of production must be balanced by an equal rate of aqueous humor drainage. Small variations in the production or outflow of aqueous humor will have a large influence on the intraocular pressure. The drainage route for aqueous humor flow is first through the posterior chamber, then the narrow space between the posterior iris and the anterior lens (contributes to small resistance), through the pupil to enter the anterior chamber. From there, the aqueous humor exits the eye through the trabecular meshwork into Schlemm's canal (a channel at the limbus, i.e., the joining point of the cornea and sclera, which encircles the cornea). It flows through 25–30 collector canals into the episcleral veins. The greatest resistance to aqueous flow is provided by the trabecular meshwork (esp. the juxtacanalicular part), and this is where most of the aqueous outflow occurs. The internal wall of the canal is very delicate and allows the fluid to filter due to the high pressure of the fluid within the eye. The secondary route is the uveoscleral drainage, and is independent of the intraocular pressure, the aqueous flows through here, but to a lesser extent than through the trabecular meshwork (approx. 10% of the total drainage whereas by trabecular meshwork 90% of the total drainage). The fluid is normally 15 mmHg (0.6 inHg) above atmospheric pressure, so when a syringe is injected the fluid flows easily.
Claire Darke, former mayor of Wolverhampton and a longtime Labour councillor, resigns from the Labour Party, citing disillusionment with its direction under Keir Starmer. She specifically criticizes the party's stance on austerity and its "morally wrong" position on Gaza, which she sees as neglecting the suffering of the Palestinian people. 25 June – Emperor Naruhito and Empress Masako of Japan begin their state visit to the United Kingdom. 2024 United Kingdom general election date betting controversy: The Conservative Party withdraws its support for Craig Williams and Laura Saunders as election candidates. Cabinet minister Alister Jack, who previously said he had won £2,100 by betting on the date of the election, then said he was joking, issues a statement in which he says he did not place a bet on the election. Russell George, the Senedd member for Montgomeryshire, becomes the fifth Conservative politician to be investigated by the Gambling Commission for election betting. The Metropolitan Police confirms that the Gambling Commission are investigating a further five police officers for placing bets on the date of the election. Labour suspends Kevin Craig, their candidate for Central Suffolk and North Ipswich, after the Gambling Commission launches an unrelated investigation into him for placing a bet against himself losing in his constituency. LBC's Nick Ferrari moderates an immigration policy debate between Home Secretary James Cleverly and Shadow Home Secretary Yvette Cooper.
The original gun-type plutonium weapon, code-named "Thin Man", had to be abandoned as a result—the increased number of spontaneous neutrons meant that nuclear pre-detonation (fizzle) was likely. The entire plutonium weapon design effort at Los Alamos was soon changed to the more complicated implosion device, code-named "Fat Man". In an implosion bomb, plutonium is compressed to high density with explosive lenses—a technically more daunting task than the simple gun-type bomb, but necessary for a plutonium bomb. Uranium, by contrast, can be used with either method. Construction of the Hanford B Reactor, the first industrial-sized nuclear reactor for the purposes of material production, was completed in March 1945. B Reactor produced the fissile material for the plutonium weapons used during World War II. B, D and F were the initial reactors built at Hanford, and six additional plutonium-producing reactors were built later at the site. By the end of January 1945, the highly purified plutonium underwent further concentration in the completed chemical isolation building, where remaining impurities were removed successfully. Los Alamos received its first plutonium from Hanford on February 2. While it was still by no means clear that enough plutonium could be produced for use in bombs by the war's end, Hanford was by early 1945 in operation. Only two years had passed since Col. Franklin Matthias first set up his temporary headquarters on the banks of the Columbia River.
Sources: en.wikipedia.org
On 23 January 2026, Danish prime minister Mette Frederiksen visited Greenland to express support for the people and the island's self-governing government, following comments by US president Donald Trump indicating his willingness to annex the territory. Trump had previously discussed strengthening security in the Arctic region with NATO secretary general Mark Rutte. Both the Danish and Greenlandic governments have affirmed that the island's sovereignty is indisputable, but remain open to discussions on issues such as security and economic development. The crisis eased after Trump withdrew threats of force and new tariffs.
=== Bankruptcy === In September 2024, TGI Fridays lost day-to-day control of its assets after failing to submit documents to bondholders on time, with consulting firm FTI Consulting taking temporary control. As a result, Hostmore LLC, the owner of TGI Friday's UK restaurants, dropped its plans to acquire TGI Fridays and went into administration, putting an estimated 4,500 jobs at risk. A month later, on October 7, 2024, private equity firms Calveton UK and Breal Capital acquired 51 sites and saved 2,389 jobs, but didn't acquire 35 sites which immediately closed, resulting in the loss of 1,012 jobs. On October 19, 2024, TGI Fridays announced it was seeking financing as it warned that it was preparing to file for Chapter 11 bankruptcy in the United States within the coming weeks. The company blamed its bankruptcy on rising interest rates, increased competition and heavy debt. On November 2, 2024, TGI Fridays filed for Chapter 11 bankruptcy. The company's press release specifically cited its capital structure as one primary driver of its bankruptcy filing. On January 2, 2025, it was announced that former CEO Ray Blanchette and his company Sugarloaf Hospitality – which owns seven TGI Fridays franchised restaurants in the US – had been chosen to manage all of TGI Friday's franchised restaurants worldwide. It was also announced that nine of the company's 39 corporate-owned restaurants had been sold to MERA Corp, a TGI Fridays franchisee based in Cancún, Mexico, for $34.5 million, outbidding Blanchette – who had made a bid of $30 million – for the locations.
== Epidemiology == Cardiac myxomas predominantly appear in females in their 30s to 40s. Myxomas are the most common primary cardiac tumor affecting adults, accounting for one quarter to half of primary cardiac tumors seen in clinical practice.
VIP is highly localised in lungs (70%) and binds with alveolar type II (AT II) cells via VPAC1. The biological (vasodilator) activity of vasoactive intestinal peptide (VIP) was discovered in the lungs before the peptide was isolated and chemical identity characterized from intestine. VIP levels are also considerably high in the brain and the gut. It is localized in key sites in the lung, has potent activities on its major functions, and appears to play an important role in pulmonary physiology and disease. The principal localization of VIP-containing neurons in the tracheobronchial tree is in the smooth muscle layer, around submucosal mucous glands and in the walls of pulmonary and bronchial arteries. Immunoreactive VIP is also present in neuronal cell bodies forming microglia that provide a source of intrinsic innervation of pulmonary structures.
The human NDUFB4 gene codes for a subunit of Complex I of the respiratory chain, which transfers electrons from NADH to ubiquinone. However, NDUFB4 is an accessory subunit of the complex that is believed not to be involved in catalysis. Mammalian complex I is composed of 45 different subunits. It locates at the mitochondrial inner membrane. This protein complex has NADH dehydrogenase activity and oxidoreductase activity. It transfers electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Initially, NADH binds to Complex I and transfers two electrons to the isoalloxazine ring of the flavin mononucleotide (FMN) prosthetic arm to form FMNH2. The electrons are transferred through a series of iron-sulfur (Fe-S) clusters in the prosthetic arm and finally to coenzyme Q10 (CoQ), which is reduced to ubiquinol (CoQH2). The flow of electrons changes the redox state of the protein, resulting in a conformational change and pK shift of the ionizable side chain, which pumps four hydrogen ions out of the mitochondrial matrix.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.